82846-28-4

Usage

Uses

Used in Pharmaceutical Industry:
6-(Dimethylamino)nicotinic acid is used as an intermediate compound for the synthesis of various pharmaceuticals, contributing to the development of new drugs and medications. Its unique chemical structure allows for versatile applications in drug formulation and synthesis.
Used in Chemical Synthesis:
6-(Dimethylamino)nicotinic acid is used as a building block in the synthesis of complex chemical compounds, particularly in the field of organic chemistry. Its Dimethylamino functional group plays a crucial role in the formation of chemical polymers and other advanced materials.
Used in Research and Development:
6-(Dimethylamino)nicotinic acid is utilized in scientific research and development, particularly in the study of chemical reactions and the exploration of new chemical pathways. Its properties and reactivity make it a valuable tool for researchers in the field of chemistry and related disciplines.

InChI:InChI=1/C8H10N2O2/c1-10(2)7-4-3-6(5-9-7)8(11)12/h3-5H,1-2H3,(H,11,12)

Upstream product

• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 124-40-3 dimethyl amine 
• 6311-35-9 6-bromonicotinic acid 
• 7647-01-0 hydrogenchloride 

Downstream Products

• 246034-30-0 6-dimethylamino-nicotinoyl chloride 
• 1054611-48-1 C₃₃H₃₈N₆O₄ 

Relevant academic research and scientific papers

BTK protein kinase inhibitors

This application discloses pyridine and pyrimidine compounds according to formula I wherein R1, R2, R3, R4, R5, X1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.

DICARBONYLIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY

Compounds of formula (I), and their pharmaceutically acceptable salts and solvates, wherein X represents -O-, -NH-, -S-, -NHC(=O)- or -NHC(=S)-; R1 represents -H or a hydrocarbon chain; R2 represents -H, alkoxy, amino, a hydrocarbon chain or a radical of a cycle; R3 represents -H, a hydrocarbon chain or a radical of a cycle; R4 represents -H or a hydrocarbon chain; alternatively R3 and R4 form together a cycle; R5 and R6 represent -H or halogen, and R7 represents -H, a hydrocarbon chain or heteroaryl, are useful against bacterial infections in animals, including humans.

3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b

A series of 3-nitro-4-substituted-aminobenzoic acids were prepared and found to act as potent and highly selective agonists of the orphan human GPCR GPR109b, a low affinity receptor for niacin. No activity was observed at the closely homologous high affinity niacin receptor, GPR109a. A second series, comprising 6-amino-substituted nicotinic acids was, also prepared and several analogues showed comparable activity to the nitroaryl series.

Synthesis of N-acetylglucosaminyl and diacetylchitobiosyl amides of heterocyclic carboxylic acids as potential chitinase inhibitors

2-(Dimethylammo)oxazoline-4-carboxylic acids 5 were prepared by condensation of binucleophilic amino acids 4 and O-ethyl-N,N-dimethyhsourea 3. New heterocyclic N-acetylglucosaminyl amides and chitobiosyl amides 8 were obtained by the coupling of tetraacetylglucosamine 6a or heptaacetylchitobiosylamine 6b with acid chlorides of heterocyclic carboxylic acids 2 or 5a and subsequent deacetylation. Based on their substitution patterns, compounds 8 were expected to have inhibitory activity towards chitinases. Enzyme assays showed that glycosyl amides 8 indeed were moderate inhibitors of chitinases, the diacetylchitobiosyl amides 8d-f generally having higher inhibitory activities than the N-acetylglucosaminyl amide derivatives 8a-c. Inhibitory activities depended on the chitinase tested.